Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MK-7602 CHMI study in healthy adults
NCT06294912Phase 1Completed
- Sponsor
- Merck & Co.
- Start
- Apr 2024
- Primary completion
- Jan 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of MK-7602 in malaria (8 arms), sponsored by Merck & Co. Primary endpoints: Parasite Reduction Ratio at 48 hours, Parasite Clearance Half-life at 96 hours and 3 more. Started Apr 2024; status: completed.
02
Drugs
MK-7602
03
Conditions
malaria
Beyond the preview
Go deeper on NCT06294912.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06294912.